default author photo

Ellen Townley

Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID)

Bethesda, MD 20892-9806

United States

  • Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID)

SCHOLARLY PAPERS

1

DOWNLOADS

67

TOTAL CITATIONS

3

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Dolutegravir Dispersible Tablets in Infants and Children with HIV-1: Results of the IMPAACT P1093 Study, a Phase I/II Open-Label Trial

Number of pages: 24 Posted: 10 Nov 2021
Theodore Dumont Ruel, Edward P. Acosta, Jessica P. Liu, Kathryn P. Gray, Kathleen George, Nicole Montañez, Stephanie Popson, Ann M. Buchanan, Mattie Bartlett, Dale Dayton, Patricia Anthony, Cynthia Brothers, Cynthia Vavro, Rajendra Singh, Lucy Koech, Tichaona Vhembo, Rohan Hazra, Ellen Townley, Andrew Wiznia and IMPAACT P1093 Team
University of California, San Francisco (UCSF), University of Alabama at Birmingham, Frontier Science & Technology Research Foundation, Harvard T.H. Chan School of Public Health, FHI 360, FHI 360, Frontier Science & Technology Research Foundation, ViiV Healthcare Ltd., Frontier Science & Technology Research Foundation, University of California, Los Angeles (UCLA), University of Southern California, ViiV Healthcare Ltd., ViiV Healthcare Ltd., ViiV Healthcare Ltd., Kenya Medical Research Institute (KEMRI) - Kenya Medical Research Institute (KEMRI)/Walter Reed Project, University of Zimbabwe, Government of the United States of America - Eunice Kennedy-Shriver National Institutes of Child Health and Human Development, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Yeshiva University - Jacobi Medical Center and Independent
Downloads 67 (899,324)
Citation 3

Abstract:

Loading...

Dolutegravir, infants, children, HIV-1, HIV